Elbit Imaging Ltd (EMITF)

[midastouch017]

Elbit Imaging Ltd. Announces FDA Approval of Insightec's Phase I Clinical Trial for the Treatment of Neuropathic Pain

TEL AVIV, ISRAEL / ACCESSWIRE / June 26, 2017 / Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that the FDA has approved the commencement of Phase I clinical trial for the treatment of neuropathic pain by INSIGHTEC's Exablate Neuro system (the "Trial"). The Trial will include 10 patients and will be fund by the Focused Ultrasound Foundation. INSIGHTEC is the regulatory sponsor of the clinical Trial. The purpose of the Trial is to examine the safety and the efficiency of the treatment.
INSIGHTEC cannot estimate at this stage when the Trial will actually commence and when the first patient will be recruited.

Exablate Neuro uses focused ultrasound waves to precisely target and ablate tissue deep within the brain with no incisions or implants. The treatment is done under MRI guidance for real time treatment monitoring.

The Company holds approximately 89.7% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M) (86.1% on a fully diluted basis) which, in turn, holds approximately 31.3% of the share capital in INSIGHTEC (26.6% on a fully diluted basis).